All three tenses have at least two readings, so the archetype blend applies as printed.
All nine metrics read as filed from the record.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2017-08-29.
From the record
Bio-Techne Corp's filings since 2017 show 1 warning event: a late-report notice (Form NT 10-K or NT 10-Q, the latest 2017-08-29) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+8.9% a year over 10 filed years; profitable in 10 of 10.
From the record
Bio-Techne Corp's 10 filed years say what it did: revenue went from $563 million in fiscal 2017 to $1.2 billion in fiscal 2026, up 8.9% a year; it rose in 8 of 9 years; the deepest fall was 0% from fiscal 2025 to fiscal 2026; net income was positive in 10 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
Share count shrank 1.0% a year. 62% of cash flow returned. Insiders: 2 sales, 0 purchases.
From the record
Over the 3 fiscal years to 2026-06-30, Bio-Techne Corp's diluted share count shrank about 1.0% a year, and dividends and buybacks returned about 62% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 2 sales and 0 purchases of their own stock on the open market in the year to 2026-11-03 (their Form 4 filings).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they doing right now?
Is it financially healthy right now?
ROE 9%: 9¢ of profit per shareholder dollar. Leverage 18%: owes 18¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2026-06-30, Bio-Techne Corp earned about 9 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 31 cents per dollar of everything the company owns. Leverage: it owed about 18 cents per dollar of assets, and net share issuance: its share count shrank 1.7% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 26% of 102 in its family; net margin 15%.
From the record
Bio-Techne Corp's standing among 102 graded names in its industry family: revenue of $1.2 billion in fiscal 2026 ranks in the top 8% by size; a net margin of 15% ranks in the top 16%; revenue growth of 2.2% a year over the last 3 filed years ranks in the bottom 46% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 47% of 110 in its family for leadership; chief executive since 2024.
From the record
Bio-Techne Corp's leadership, from its insiders' filings and its current reports: the chief executive on the record is Kelderman, Kim (Chief Executive Officer, as filed), filing under that title since 2024-08-02, 2.3 years (bottom 28% of its family); the 15 officers and directors filing in the last fifteen months have been on the record a median of 7.4 years (top 20%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 15 people in charge now (top 50%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 37% of 92 in its family for room to expand.
From the record
Bio-Techne Corp's room to grow, from the newest filed statements (fiscal 2026): cash of $265 million against debt of $200 million leaves 2.5% of its assets as net cash, bottom 10% of its family; cash from operations less capital spending is 21.7% of revenue (top 11%); a gross margin of 65.8% (bottom 46%); research spending of 7.8% of revenue (bottom 6%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 49% of 100 in its family for growth drivers.
From the record
Bio-Techne Corp's growth drivers, from the filed years to fiscal 2026: revenue grew 2.2% a year over the last three filed years against 8.9% over all 10, slowing (top 50% of its family); the newest year grew -0.4% (bottom 34%); research spending grew 0.8% a year (top 49%); capital spending grew -9% a year (top 30%) (its annual reports). Bio-Techne Corp reported 4 product lines in fiscal 2026: Consumables at $985 million (81%), Instruments at $111 million (9%), Service at $94 million (8%), and 1 more; 2 of 4 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 39% of 72 in its family for expectations against reality.
From the record
Bio-Techne Corp's newest year against its own record: revenue of $1.2 billion in fiscal 2026 came in 3.8% below the $1.3 billion its prior three years' pace pointed to (bottom 37% of its family); net income of $182 million against a prior three-year average of $176 million (bottom 47%); a net margin of 15% against 15.2% before (bottom 34%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made